4,474 results match your criteria Biol. Blood Marrow Transplant.[Journal]


Outcomes of Related and Unrelated Donor Searches Among Patients with Primary Immunodeficiency Diseases Referred for Allogeneic Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2019 Apr 12. Epub 2019 Apr 12.

National Institutes of Health, Bethesda, Maryland. Electronic address:

Introduction: Patients with primary immunodeficiencies (PIDs) are potentially cured by allogeneic hematopoietic cell transplantation (HCT). The spectrum of PIDs has expanded greatly beyond those that present in infancy or are diagnosed on newborn screening and require urgent, preemptive HCT. Many PID diagnoses are now made later in life and the role of HCT is only considered upon severe disease manifestations; in these cases, the kinetics and goals of a donor search may be different than for severe combined immunodeficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.04.008DOI Listing

Efficacy, toxicity and infectious Complications in Ruxolitinib Treated Patients with Corticosteroid-refractory Graft-versus-host Disease after Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2019 Apr 6. Epub 2019 Apr 6.

Blood & Marrow Transplantation and Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.

Corticosteroid-refractory GVHD (SR-GVHD) remains a significant source of morbidity after allogeneic hematopoietic cell transplantation (HCT). No standard therapy exists in this setting, however recent studies have demonstrated a very promising role for ruxolitinib, an oral Janus Kinase (JAK) 1/2 inhibitor. With increasing evidence of efficacy for SR-GVHD, limited data exists describing complications of ruxolitinib use, and specifically infectious complications during use in SR-GVHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.04.003DOI Listing

Reply to: Pharmacological considerations in antithymocyte globulin exposure calculation.

Biol Blood Marrow Transplant 2019 Apr 6. Epub 2019 Apr 6.

Alberta Blood and Marrow Transplant Program & University of Calgary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.04.002DOI Listing

Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplant-Eligible Patients.

Biol Blood Marrow Transplant 2019 Apr 6. Epub 2019 Apr 6.

Departments of Oncology and Medicine, University of Calgary, Alberta.

While no widely accepted standard treatment regimen exists for primary CNS lymphoma (PCNSL), growing evidence supports one that incorporates autologous stem cell transplant (ASCT) as consolidative therapy when feasible. In November 2011, the Alberta Hematology Tumor Team established a new clinical practice guideline (CPG) for PCNSL involving high dose methotrexate (HDMTX)/cytarabine-based induction followed by ASCT for eligible patients using a thiotepa and busulfan (TBu) conditioning regimen that omitted cyclophosphamide from the regimen that was used prior to 2011. This retrospective study analyzed all 64 PCNSL patients consecutively diagnosed in three Canadian centers between November 2011 and December 2017 to evaluate adherence to the 2011 CPG and associated outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.04.004DOI Listing
April 2019
1 Read

Gastrointestinal Microbiome and Mycobiome changes during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study.

Biol Blood Marrow Transplant 2019 Apr 5. Epub 2019 Apr 5.

Stem Cell Transplant Program, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio, USA. Electronic address:

Microbiome dysbiosis has been associated with adverse hematopoietic cell transplantation outcomes. We hypothesized that exposure to high-dose melphalan and antimicrobials in patients undergoing autologous HCT for plasma cell disorders results in oral and gastrointestinal microbial dysbiosis that is in turn associated with regimen-related toxicities. We conducted a prospective study describing the longitudinal changes in oral and gastrointestinal bacteriome and mycobiome in this patient population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.04.007DOI Listing
April 2019
3 Reads

A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.

Biol Blood Marrow Transplant 2019 Apr 5. Epub 2019 Apr 5.

Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address:

The programmed death-1 (PD-1) axis can suppress immune surveillance against multiple myeloma (MM). We tested the safety and efficacy of pembrolizumab, an anti-PD-1 antibody, in MM after autologous hematopoietic cell transplantation (AHCT). We enrolled MM patients not achieving complete response (CR) to induction to receive 9 doses of 3- weekly IV pembrolizumab starting day 14 post-AHCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.04.005DOI Listing
April 2019
1 Read

Health Care Utilization is High in Adult Patients Relapsing After Allogeneic Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2019 Apr 5. Epub 2019 Apr 5.

Division of Blood and Marrow Transplantation, Department of Medicine, Stanford, CA.

Disease relapse is the leading cause of death for patients with acute leukemia (AL) and myelodyspastic syndrome (MDS) who undergo allogeneic hematopoietic cell transplantation (HCT). Relapse post-HCT is associated with poor prognosis; however, the inpatient health care utilization of this population is unknown. Here we describe survival, intensity of health care utilization, and characteristics associated with high resource utilization at the end-of-life (EOL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.04.001DOI Listing
April 2019
1 Read

Safety and seropositivity after live attenuated vaccine in adult patients receiving hematopoietic stem cell transplantation.

Biol Blood Marrow Transplant 2019 Apr 5. Epub 2019 Apr 5.

Department of Medicine and Biosystemic Science, Graduate School of Medical Science, Kyushu University, Fukuoka. Electronic address:

Vaccination against vaccine-preventable diseases (VPDs) is highly recommended for hematopoietic stem cell transplantation (HSCT) recipients by several guidelines; however, the safety and seropositivity after live attenuated vaccines remain unclear in adult HSCT recipients. We analyzed titers of antibodies against measles, rubella, mumps, and varicella zoster virus (VZV) from Japanese adult patients who underwent allogeneic HSCT (allo-HSCT) (n = 74), autologous HSCT (auto-HSCT) (n = 39), or chemotherapy (n = 93). The seropositive rates for measles, rubella, mumps, and VZV in allo-HSCT recipients were 20. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.04.006DOI Listing
April 2019
1 Read

Corrigendum to 'Interferon α: A potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation' [Biology of Blood and Marrow Transplantation 21/11 (2015) 1939-1947].

Biol Blood Marrow Transplant 2019 Apr 4. Epub 2019 Apr 4.

Peking University People's Hospital & Peking University Institute of Hematology, Beijing, China; Peking-Tsinghua Center for Life Sciences, Beijing, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.007DOI Listing
April 2019
1 Read

Corrigendum to 'Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus host disease guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed Acute Leukemia' [Biology of Blood and Marrow Transplantation 23/8 (2017) 1311-1319].

Biol Blood Marrow Transplant 2019 Apr 4. Epub 2019 Apr 4.

Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Collaborative Innovation Center of Hematology, Beijing, China; Nanfang Hospital, Southern Medical University, Beijing, China; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Beijing, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.006DOI Listing
April 2019
2 Reads

Corrigendum to 'Interferon-α is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: results of a registry study' [Biology of Blood and Marrow Transplantation 23/8 (2017) 1303-1310].

Biol Blood Marrow Transplant 2019 Apr 3. Epub 2019 Apr 3.

Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.005DOI Listing
April 2019
1 Read

Unrelated donor peripheral blood stem cell transplantation for patients with β-thalassaemia major based on a novel conditioning regimen.

Biol Blood Marrow Transplant 2019 Apr 2. Epub 2019 Apr 2.

Department of Hematology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, PR China; Department of Pediatric Hematology-Oncology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, PR China. Electronic address:

Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is the only available curative treatment for patients with β-thalassemia major (β-TM). However, the problem of finding a suitable sibling donor (SD) with well-matched human leukocyte antigens (HLAs) is still a major obstacle to curing these patients. With the progress in high-resolution HLA typing technology and supportive care, outcomes after allo-HSCT from a HLA-well-matched unrelated donor (UD) now approach those of well-matched SDs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.028DOI Listing
April 2019
1 Read

Donor-derived CIK Cell Infusion as Consolidation after Non-myeloablative Allogeneic Transplant for Myeloid Neoplasms.

Biol Blood Marrow Transplant 2019 Apr 2. Epub 2019 Apr 2.

Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA. Electronic address:

Non-myeloablative conditioning, such as with total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG), has allowed hematopoietic allotransplantation with curative potential for older patients and those with comorbid medical conditions with myeloid neoplasms. However, early achievement of full donor chimerism (FDC) and relapse remain challenges. Cytokine induced killer (CIK) cells have been shown to have anti-tumor cytotoxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.027DOI Listing
April 2019
1 Read

Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal.

Biol Blood Marrow Transplant 2019 Mar 26;25(3):570-576. Epub 2018 Oct 26.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington; Division of Nephrology, Seattle Children's Hospital, Seattle, Washington.

Transplant-associated thrombotic microangiopathy (TA-TMA) after allogeneic hematopoietic cell transplantation (HCT) has not been well characterized in large population studies with clinically adjudicated cases. We performed a retrospective cohort study of adults who underwent allogeneic HCT between 2006 and 2015 to determine the incidence of and risk factors for TA-TMA and to describe its natural history and response to immunosuppressant withdrawal management. Among 2145 patients in this study, 192 developed TA-TMA with a cumulative incidence of 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.10.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450411PMC
March 2019
2 Reads

INFLUENCE OF DONOR AND RECIPIENT GENDER ON TELOMERE MAINTENANCE FOLLOWING UMBILICAL CORD BLOOD CELL TRANSPLANTATION: A STUDY BY GITMO (GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO).

Biol Blood Marrow Transplant 2019 Mar 29. Epub 2019 Mar 29.

Oncohematology Division, IEO European Institute of Oncology, IRCCS, Milan; University of Milan, Milano, Italy. Electronic address:

Physiological loss of telomerase activity in adult life determines progressive telomere length (TL) shortening. Inflammation and oxidative damage are established causes of TL loss; moreover, males have shorter telomeres compared to females. Despite these notions, mechanisms regulating TL maintenance are poorly defined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.026DOI Listing

Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study.

Biol Blood Marrow Transplant 2019 Mar;25(3):443-450

Anthony Nolan Research Institute, Royal Free Hospital, London, United Kingdom; UCL Cancer Institute, Royal Free Campus, London, United Kingdom. Electronic address:

HLA matching at an allelic-level resolution for volunteer unrelated donor (VUD) hematopoietic cell transplantation (HCT) results in improved survival and fewer post-transplant complications. Limitations in typing technologies used for the hyperpolymorphic HLA genes have meant that variations outside of the antigen recognition domain (ARD) have not been previously characterized in HCT. Our aim was to explore the extent of diversity outside of the ARD and determine the impact of this diversity on transplant outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.12.768DOI Listing
March 2019
3.404 Impact Factor

Comparison of DIPSS and MYSEC-PM for prediction of outcome in post-PV and ET myelofibrosis after allogeneic stem-cell transplantation.

Biol Blood Marrow Transplant 2019 Mar 28. Epub 2019 Mar 28.

University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address:

We aimed to validate the MYelofibrosis SECondary to PV and ET prognostic model (MYSEC- PM) in 159 patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET) from the European Society for Blood and Marrow Transplantation registry undergoing transplantation from matched siblings or unrelated donors. Furthermore, we aimed to test its prognostic performance in comparison with the Dynamic International Prognostic Scoring System (DIPSS). Score performance was analyzed using the concordance index (C): the probability that a patient who experienced an event had a higher risk score than a patient who did not (C >0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.024DOI Listing
March 2019
2 Reads

Pharmacological considerations in antithymocyte globulin exposure calculation.

Biol Blood Marrow Transplant 2019 Mar 27. Epub 2019 Mar 27.

Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.023DOI Listing

Influence of donor type (sibling vs matched-unrelated donor vs haplo-identical donor) on outcomes after clofarabine-based reduced-intensity conditioning allograft for myeloid malignancies.

Biol Blood Marrow Transplant 2019 Mar 27. Epub 2019 Mar 27.

Hematology Department, CHU, Nantes, France; Nantes-Angers Cancer Research Center (CRCINA), University of Nantes, Inserm UMR1232, 8 quai Moncousu, 44007 Nantes, France. Electronic address:

Clofarabine-based reduced-intensity conditioning (RIC) regimens are well-established schedules for allograft in patients with myeloid malignancies. A retrospective study was conducted including all adults allografted in our department with such a regimen and disease with the aim to assess whether or not the donor type (matched sibling (MSD), unrelated (MUD), or haploidentical (haplo)) impacted outcomes. Between October 2009 and February 2018, 118 patients met the inclusion criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.025DOI Listing
March 2019
1 Read

The pre-treatment CD34+/CD38- cell burden as prognostic factor in MDS patients receiving allogeneic stem cell transplantation.

Biol Blood Marrow Transplant 2019 Mar 27. Epub 2019 Mar 27.

Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany.

Myelodysplastic syndrome (MDS) is a highly heterogeneous clonal hematopoietic disorder. Allogeneic stem cell transplantation (HSCT) remains the only curative treatment, and is of particular interest in patients at high risk for progression to acute myeloid leukemia (AML). In MDS, CD34+/CD38- cells possess MDS stem cell potential and secondary AML (sAML) clones originate from MDS disease stage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.022DOI Listing
March 2019
2 Reads

Comparable outcomes of first-line hematopoietic stem cell transplantation from unrelated and matched sibling donors in adult patients with aplastic anemia: A retrospective single-centre study.

Biol Blood Marrow Transplant 2019 Mar 26. Epub 2019 Mar 26.

Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China. Electronic address:

To explore the feasibility of upfront unrelated donor (URD) hematopoietic stem cell transplantation (HSCT) in the treatment of adult aplastic anemia (AA), we conducted a retrospective, single-centre study and compared the outcomes of adult patients who underwent first-line URD HSCT or matched sibling donor (MSD) HSCT between August 2012 and June 2018. In all, 23 URD HSCT recipients had an increased cumulative incidence of grade II acute graft-versus-host disease (aGVHD, 21.7% vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.020DOI Listing
March 2019
1 Read

Risks and outcomes of allogeneic hematopoietic stem cell transplantation for hematologic malignancies in patients with Human immunodeficiency virus Infection.

Biol Blood Marrow Transplant 2019 Mar 26. Epub 2019 Mar 26.

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN; Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, SA. Electronic address:

Allogeneic hematopoietic cell transplantation (Allo-HCT) is a potentially curative therapy for hematologic malignancies in persons living with human immunodeficiency virus (PLHIV), however, uncertainties exist in many domains related to their care, including optimal donor selection, conditioning regimen, immunosuppression for graft-versus-host disease (GVHD) and long-term outcomes. We undertook a comprehensive systematic review from multiple databases to evaluate the above-mentioned uncertainties. Forty-nine patients (median age 34 years at HCT) were included in the final sample size. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.021DOI Listing
March 2019
1 Read

Reduced plasma amino acid levels during allogeneic haematopoietic stem cell transplantation are associated with systemic inflammation and treatment-related complications.

Biol Blood Marrow Transplant 2019 Mar 22. Epub 2019 Mar 22.

Institute for Inflammation Research, Department of Rheumatology and Spine Disease, Rigshospitalet, Denmark; Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Denmark.

Patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) are challenged by cytotoxic effects of the conditioning regimen, resulting in tissue damage, systemic inflammation and elevated metabolic demands for amino acids to regenerate damaged tissues, reconstitute hematopoietic cells, and establish antioxidant defenses. Few studies have addressed the role of plasma amino acid (PAA) levels during transplantation, and it remains unknown if amino acid deficiency can aggravate treatment-related morbidity. We determined plasma levels of the 23 human amino acids in 80 HSCT patients (age 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.018DOI Listing
March 2019
1 Read

Comparing a neutropenic diet to a food safety-based diet in pediatric patients undergoing hematopoietic stem cell transplantation.

Biol Blood Marrow Transplant 2019 Mar 22. Epub 2019 Mar 22.

Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.

Introduction: Neutropenic diets were adopted as a way to decrease the infection risks in immunocompromised individuals, however, these diets result in significant restrictions in the variety and types of foods an individual may consume.

Methods: We utilized a controlled before-and-after study design in consecutive pediatric and young adult patients who underwent hematopoietic stem cell transplant (HSCT) at our center between January 1, 2014 and December 31, 2014. From January through June, all patients were placed on a traditional neutropenic diet, on July 1, we liberalized the BMT diet to a modified bone marrow transplant (BMT) diet. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.017DOI Listing
March 2019
1 Read

Authors' Response to the Letter-to-the-Editor by Brown ART and Gutierrez C.

Biol Blood Marrow Transplant 2019 Mar 22. Epub 2019 Mar 22.

The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.019DOI Listing

A phase I/II, open-label, prospective, multicenter study to evaluate the efficacy and safety of lower doses of bortezomib plus busulfan and melphalan as a conditioning regimen in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation: The KMM103 study.

Biol Blood Marrow Transplant 2019 Mar 22. Epub 2019 Mar 22.

Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea. Electronic address:

A phase I/II trial was conducted to explore the safety and activity of addition of bortezomib on days -6, -3, and +1 relative to the day of autologous stem cell transplantation to a conditioning regimen with busulfan and melphalan (BuMel; 3.2 mg/kg/day busulfan on days -5 to -3 and 140 mg/m/day melphalan on day -2) in patients with multiple myeloma (MM) following bortezomib-based induction chemotherapy. In phase I, doses of bortezomib (0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.016DOI Listing
March 2019
5 Reads

Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia.

Biol Blood Marrow Transplant 2019 Mar 15. Epub 2019 Mar 15.

Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, Germany.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for patients with advanced myelodysplastic syndrome (MDS) and secondary acute myelogenous leukemia (sAML), but in the absence of prospective trials the impact of pretransplant cytoreduction is controversially discussed. We retrospectively analyzed the outcome of 165 patients with MDS and excess blasts (n = 126, 76%) and sAML (n = 39, 24%) according to a pretransplant strategy. Sixty-seven patients (41%) were directly transplanted (upfront group), whereas 98 patients (59%) had received pretransplant cytoreductive treatment (induction chemotherapy [CTX], n = 64; hypomethylating agents [HMAs], n = 34) resulting in a significantly higher complete remission rate in the CTX group (59% versus HMA 18%, P < . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.011DOI Listing
March 2019
1 Read

Screening for Family Psychosocial Risk in Pediatric Hematopoietic Stem Cell Transplantation with the Psychosocial Assessment Tool.

Biol Blood Marrow Transplant 2019 Mar 14. Epub 2019 Mar 14.

Nemours Children's Health System, Wilmington, Delaware; Sidney Kimmel Medical School at Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address:

Family psychosocial risk screening is an important initial step in delivering evidence-based care in hematopoietic stem cell transplantation (HCT). Establishing an evidence-based screening approach that is acceptable, reliable, and valid is an essential step in psychosocial care delivery. This is a 3-institution multimethod study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.012DOI Listing

Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions.

Biol Blood Marrow Transplant 2019 Mar 13. Epub 2019 Mar 13.

Division of Stem Cell Transplantation and Immunology, Department of Children and Adolescents, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany. Electronic address:

Well-established donor lymphocyte infusion (DLI) and novel cytokine-induced killer (CIK) cell therapy for the treatment of relapsing hematologic malignancies after allogeneic hematopoietic stem cell transplantation (HSCT) were compared with respect to feasibility, safety, and efficacy. Altogether, a total of 221 infusions were given to 91 patients (DLI, n = 55; CIK, n = 36). T cell recovery was significantly improved after CIK cell therapy (P < . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.004DOI Listing
March 2019
1 Read

Protecting the Selfless: Toward More Comprehensive Care for Pediatric Related Stem Cell Donors.

Authors:
Leslie Lehmann

Biol Blood Marrow Transplant 2019 Mar 14. Epub 2019 Mar 14.

Dana-Farber/Children's Hospital Boston, Boston, Massachusetts. Electronic address:

None. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.010DOI Listing

Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation.

Biol Blood Marrow Transplant 2019 Mar 14. Epub 2019 Mar 14.

Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.

Alternative donor allogeneic hematopoietic cell transplants (HCTs), such as double umbilical cord blood transplants (dUCBT) and haploidentical related donor transplants (haplo-HCT), have been shown to be safe and effective in adult patients who do not have an HLA-identical sibling or unrelated donor available. Most transplant centers have committed to 1 of the 2 alternative donor sources, even with a lack of published randomized data directly comparing outcomes and comparative data on the cost-effectiveness of dUCBT versus haplo-HCT. We conducted a retrospective study to evaluate and compare the early costs and charges of haplo-HCT and dUCBT in the first 100days at 2 US transplant centers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.013DOI Listing
March 2019
1 Read

A Tale of Two Eras: The Story of Autologous Stem Cell Transplantation with and without Thiotepa for Primary Central Nervous System Lymphoma.

Authors:
Bei Hu

Biol Blood Marrow Transplant 2019 Mar 14. Epub 2019 Mar 14.

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.014DOI Listing

Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency.

Biol Blood Marrow Transplant 2019 Mar 12. Epub 2019 Mar 12.

Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco Benioff Children's Hospital, San Francisco, California.

After allogeneic hematopoietic cell transplantation (HCT), the minimal myeloid chimerism required for full T and B cell reconstitution in patients with severe combined immunodeficiency (SCID) is unknown. We retrospectively reviewed our experience with low-exposure busulfan (cumulative area under the curve, 30 mg·hr/L) in 10 SCID patients undergoing either first or repeat HCT from unrelated or haploidentical donors. The median busulfan dose required to achieve this exposure was 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.008DOI Listing
March 2019
2 Reads

Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immunodeficiencies and Inherited Disorders in Children.

Biol Blood Marrow Transplant 2019 Mar 12. Epub 2019 Mar 12.

Pediatric Hematology-Immunology and Rheumatology Unit, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Paris-Descartes University, Sorbonne Paris Cité, Paris, France.

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for some inherited disorders, including selected primary immunodeficiencies (PIDs). In the absence of a well-matched donor, HSCT from a haploidentical family donor (HIFD) may be considered. In adult recipients high-dose post-transplant cyclophosphamide (PTCY) is increasingly used to mitigate the risks of graft failure and graft-versus-host disease (GVHD). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193018
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.03.009DOI Listing
March 2019
3 Reads

Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.

Biol Blood Marrow Transplant 2019 Mar 13. Epub 2019 Mar 13.

Division of Hematology, Department of Internal Medicine I, Medical University of Graz, Graz, Austria.

Chronic graft-versus-host disease (cGVHD) remains the leading cause of late morbidity and mortality. Despite the growing number of treatment options in cGVHD, evidence remains sparse. The German-Austrian-Swiss GVHD Consortium performed a survey on clinical practice in treatment of cGVHD among transplant centers in Germany, Austria, and Switzerland in 2009 and 2018 and compared the results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.003DOI Listing
March 2019
3 Reads

Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Mar 11. Epub 2019 Mar 11.

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France; INSERM, UMR 938, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie Paris 6, Paris, France. Electronic address:

We report the outcomes of 51 patients who underwent unmanipulated haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide (PT-Cy) and antithymocyte globulin (ATG), from peripheral blood stem cells (PBSCs) or bone marrow, after receipt of a TBF (thiotepa, busulfan, and fludarabine) conditioning regimen. Their median age was 55 years (range, 16 to 72 years). Hematologic diagnoses included acute leukemias (n = 31), lymphoid neoplasm (n = 12), myeloproliferative neoplasm (n = 5), and myelodysplastic syndromes (n = 3). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.025DOI Listing
March 2019
5 Reads

Etoposide + Granulocyte Colony-Stimulating Factor and Optional Plerixafor in Patients Who Failed Chemomobilization with or without Plerixafor.

Biol Blood Marrow Transplant 2019 Mar 12. Epub 2019 Mar 12.

Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania.

We conducted a retrospective study of 62 patients undergoing etoposide (2 g/m) + granulocyte colony-stimulating factor (G-CSF; 10 patients also received additional plerixafor) as a salvage stem cell mobilization regimen after previous unsuccessful chemomobilization with or without plerixafor. The median peak CD34 values after etoposide + G-CSF ± plerixafor was 54.07 CD34/μL compared with 9. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.026DOI Listing
March 2019
2 Reads

Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.

Biol Blood Marrow Transplant 2019 Mar 11. Epub 2019 Mar 11.

Clinical Research Division, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, WA, USA.

High-dose busulfan (BU) followed by high-dose cyclophosphamide (CY) before allogeneic hematopoietic cell transplantation (HCT) has long been used as treatment for hematologic malignancies. Administration of phenytoin or newer alternative antiepileptic medications (AEMs) prevents seizures caused by BU. Phenytoin induces enzymes that increase exposure to active CY metabolites in vivo, whereas alternative AEMs do not have this effect. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.001DOI Listing
March 2019
10 Reads

Circulating Heme Oxygenase-1 and Complement Activation in Transplant-Associated Thrombotic Microangiopathy.

Biol Blood Marrow Transplant 2019 Mar 12. Epub 2019 Mar 12.

The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China; Collaborative Innovation Center of Hematology, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China. Electronic address:

Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication in patients after hematopoietic stem cell transplantation. The pathogenesis of TA-TMA is still unclear. Previous studies showed that complement activation plays an important role in the development of TA-TMA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.03.002DOI Listing
March 2019
1 Read

Comments Regarding "ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells".

Biol Blood Marrow Transplant 2019 Mar 9. Epub 2019 Mar 9.

Department of Critical Care, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.027DOI Listing

Excellent Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Single-Center Study.

Biol Blood Marrow Transplant 2019 Mar 8. Epub 2019 Mar 8.

Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Collaborative Innovation Center of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China. Electronic address:

We analyzed the outcomes of 44 patients with paroxysmal nocturnal hemoglobinuria (PNH) who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) (haploidentical [haplo]-donors, 25; matched sibling donors [MSDs], 15; and matched unrelated donors, 4) between July 2007 and May 2018. All patients achieved successful donor engraftment. The median time was 12 days (range, 7 to 26) for myeloid engraftment and 13 days (range, 11 to 75) for platelets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.024DOI Listing
March 2019
1 Read

Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34 Selected Allogeneic Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2019 Mar 1. Epub 2019 Mar 1.

Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York.

Antithymocyte globulin (ATG) use mitigates the risk of graft rejection and graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT), but ATG overexposure in the setting of lymphopenia negatively affects immune recovery. We hypothesized that standard empiric weight-based dosing of ATG, used to prevent graft rejection in ex vivo CD34-selected allo-HCT, may lead to serious adverse consequences on outcomes in certain patients. We evaluated 304 patients undergoing myeloablative-conditioned ex vivo CD34-selected allo-HCT with HLA-matched donors for the treatment of hematologic malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.021DOI Listing
March 2019
3 Reads

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.

Biol Blood Marrow Transplant 2019 Mar 1. Epub 2019 Mar 1.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:

Although bortezomib and rituximab have synergistic activity in patients with lymphoma and both can attenuate graft-versus-host disease (GVHD), the drugs have not been used together in patients undergoing allogeneic stem cell transplantation (alloSCT). In this phase I/II trial, we assessed the safety and activity of bortezomib added to the rituximab (R) plus BEAM (carmustine, etoposide, cytarabine, melphalan) regimen in patients with relapsed lymphoma undergoing alloSCT. Primary GVHD prophylaxis consisted of tacrolimus and methotrexate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.022DOI Listing
March 2019
3 Reads

Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups.

Biol Blood Marrow Transplant 2019 Mar 1. Epub 2019 Mar 1.

Department of Hematology, Aiiku Hospital, Sapporo, Japan.

The choice of alternative donor is a major issue in allogeneic hematopoietic stem cell transplantation (HSCT) for patients with primary myelofibrosis (PMF) without an HLA-matched related donor. We conducted this retrospective study using the Japanese national registry data for 224 PMF patients to compare the outcomes of first allogeneic HSCT from HLA-matched related donor bone marrow (Rtd-BM), HLA-matched related donor peripheral blood stem cells (Rtd-PB), HLA-matched unrelated donor bone marrow (UR-BM), unrelated umbilical cord blood (UR-UCB), and other hematopoietic stem cell grafts. Nonrelapse mortality (NRM) rates at 1 year after Rtd-BM, Rtd-PB, UR-BM, UR-UCB, and other transplantations were 16%, 36%, 30%, 41%, and 48%, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.019DOI Listing
March 2019
3 Reads

Donor-Specific Anti-HLA Antibodies in Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: Risk of Graft Failure, Poor Graft Function, and Impact on Outcomes.

Biol Blood Marrow Transplant 2019 Mar 1. Epub 2019 Mar 1.

Bone Marrow Unit, Humanitas Cancer Center, Rozzano, Milan, Italy.

The presence of donor-specific anti-HLA antibodies (DSA) is associated with a 10-fold increased risk of graft failure in haploidentical stem cell transplantation (haplo-SCT). Consensus guidelines from the European Society for Blood and Marrow Transplantation set a mean fluorescence intensity (MFI) >1000 as a cutoff for DSA positivity. In the absence of an alternative donor, it is recommended that patients undergo desensitization therapy, especially with high DSA levels (>5000 MFI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.020DOI Listing

Nutritional and Post-Transplantation Outcomes of Enteral versus Parenteral Nutrition in Pediatric Hematopoietic Stem Cell Transplantation: A Systematic Review of Randomized and Nonrandomized Studies.

Biol Blood Marrow Transplant 2019 Mar 1. Epub 2019 Mar 1.

Centre for Health Services Research, City, University of London, London, United Kingdom.

Hematopoietic stem cell transplantation (HSCT) involves the administration of chemotherapy followed by the infusion of donor stem cells. After treatment, children can consequently experience nausea, vomiting, diarrhea, anorexia, and mucositis, which negatively impact oral intake, leading to rapid deterioration in nutritional status and risk of malnutrition. Nutrition support therefore becomes necessary to circumvent these adverse effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.023DOI Listing

Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.

Biol Blood Marrow Transplant 2019 Feb 22. Epub 2019 Feb 22.

Department of Hematology and Cell Therapy, Acute Leukemia Working Party, European Society for Blood and Marrow Transplantation, Hôpital Saint-Antoine, Paris, France.

Veno-occlusive disease, also known as sinusoidal obstruction syndrome (VOD/SOS), is a potentially life-threatening complication of allogeneic or autologous hematopoietic stem cell transplantation (HSCT) most commonly associated with high-intensity chemotherapies. The development of VOD/SOS may be rapid and unpredictable, and the importance of identifying risk factors to facilitate prompt diagnosis and timely treatment has become increasingly recognized. The reporting of new retrospective study data for adults and children and the emergence of novel anticancer therapies that may increase the risk of VOD/SOD also necessitate updates on risk factors, as provided in this review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.018DOI Listing
February 2019
2 Reads

A Conceptual Framework and Key Research Questions in Educational Needs of Blood and Marrow Transplantation Patients, Caregivers, and Families.

Biol Blood Marrow Transplant 2019 Feb 20. Epub 2019 Feb 20.

Nebraska Medicine, Omaha, Nebraska.

Patient, caregiver, and family education and support was 1 of 6 key areas of interest identified by the National Marrow Donor Program/Be The Match 2-year project to prioritize patient-centered outcomes research (PCOR) goals for the blood and marrow transplantation (BMT) community. PCOR focuses on research to help patients and their caregivers make informed decisions about health care. Therefore, each area of interest was assigned to a working group with broad representation, including patients, caregivers, and clinicians. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.017DOI Listing
February 2019
1 Read

Autologous Hematopoietic Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades.

Biol Blood Marrow Transplant 2019 Feb 20. Epub 2019 Feb 20.

Medical College of Wisconsin, Milwaukee, Wisconsin.

The curative potential of autologous hematopoietic cell transplantation (autoHCT) for male germ cell tumors (GCTs) is well established. The optimal timing and number (single transplant [ST] versus tandem transplants [TT] versus triple transplants) of autoHCT are controversial, with wide practice variations. We examined survival trends among 2395 recipients of autoHCT for male GCTs between 1990 and 2015 reported to the Center for International Blood and Marrow Transplant Research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.015DOI Listing
February 2019
5 Reads

Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant 2019 Feb 19. Epub 2019 Feb 19.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Multiple sclerosis (MS) is a chronic, disabling, immune-mediated, demyelinating and degenerative disease of the central nervous system. Approved disease-modifying therapies may be incompletely effective in some patients with highly active relapsing disease and high risk of disability. The use of immunoablative or myeloablative therapy followed by autologous hematopoietic cell transplantation (AHCT) has been investigated in retrospective studies, clinical trials, and meta-analyses/systematic reviews as an approach to address this unmet clinical need. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193013
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.02.014DOI Listing
February 2019
6 Reads